Eric L. Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric L. Chang has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Zada
Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
4 shared publications - Samuel T. Chao
Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic
4 shared publications - Wensha Yang
Department of Radiation Oncology, University of California San Francisco, San Francisco, California
4 shared publications Arjun Sahgal
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
3 shared publications- Arjun Sahgal
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
3 shared publications Cheng Yu
Neurological Surgery, University of Southern California, Los Angeles, California, UNITED STATES
3 shared publications
Latest Publications
- Open Access
GammaTile® Brachytherapy as Spatially Fractionated Radiation Therapy for Postoperative Brain Cancer: A Paradigm for Precision Intracranial Radiotherapy
Purpose: Tile-based radiation therapy (TBRT) delivers adjuvant radiation to brain tumor beds using evenly spaced cesium-131 (Cs-131) sources in collagen tiles. This study evaluated TBRT as spatially fractionated radiation therapy (SFRT) across tumor sizes and source counts. Methods and Materials: Dose distributions were generated from postoperative CT scans for 18 patients treated with TBRT, using 10–32 implanted Cs-131 sources per case (median, 20). The resection cavity (RC) was contoured on CT with registered postoperative T1-weighted MRI guidance. CTV_5mm was defined as the RC plus a 5 mm expansion excluding skull and surgical tract, and CTV_5mm_Eval as CTV_5mm minus the RC. Both volumes were analyzed using SFRT dose metrics from the Radiosurgery Society SFRT/Flash working group white paper, and planar high-dose core number density (HCND_A) was used to characterize TBRT spatial fractionation. Results: The mean dose indices of D5 (dose covering 5% of the target volume), D10, D50, D90, D95 and D100 were 175.8 ± 43.3, 148.8 ± 35.1, 86.7 ± 18.5, 56.1 ± 10.5, 50.2 ± 9.0 and 33.4 ± 7.2 Gy for the CTV_5mm_Eval, respectively. The heterogeneity indices, represented by the ratio of D5/D95 and D10/D90, were 3.5 ± 0.6 and 2.7 ± 0.4, respectively, which were in the range of the linac-based Lattice therapy. HCND_A was a constant, TBRT delivered one high dose core for every 1 cm2 of tumor bed. All dose metrics in both the CTV_5mm and CTV_5mm_Eval were largely consistent across all plans. Conclusions: TBRT produced heterogeneous dose distributions comparable to conventional SFRT. A 60 Gy TBRT nominal prescription dose approximated the SFRT D90, or valley dose of the 5 mm expansion target volume, suggesting TBRT may provide an SFRT platform for tile-accessible cancers.
Open AccessGammaTile® Brachytherapy as Spatially Fractionated Radiation Therapy for Postoperative Brain Cancer: A Paradigm for Precision Intracranial Radiotherapy
Purpose: Tile-based radiation therapy (TBRT) delivers adjuvant radiation to brain tumor beds using evenly spaced cesium-131 (Cs-131) sources in collagen tiles. This study evaluated TBRT as spatially fractionated radiation therapy (SFRT) across tumor sizes and source counts. Methods and Materials: Dose distributions were generated from postoperative CT scans for 18 patients treated with TBRT, using 10–32 implanted Cs-131 sources per case (median, 20). The resection cavity (RC) was contoured on CT with registered postoperative T1-weighted MRI guidance. CTV_5mm was defined as the RC plus a 5 mm expansion excluding skull and surgical tract, and CTV_5mm_Eval as CTV_5mm minus the RC. Both volumes were analyzed using SFRT dose metrics from the Radiosurgery Society SFRT/Flash working group white paper, and planar high-dose core number density (HCND_A) was used to characterize TBRT spatial fractionation. Results: The mean dose indices of D5 (dose covering 5% of the target volume), D10, D50, D90, D95 and D100 were 175.8 ± 43.3, 148.8 ± 35.1, 86.7 ± 18.5, 56.1 ± 10.5, 50.2 ± 9.0 and 33.4 ± 7.2 Gy for the CTV_5mm_Eval, respectively. The heterogeneity indices, represented by the ratio of D5/D95 and D10/D90, were 3.5 ± 0.6 and 2.7 ± 0.4, respectively, which were in the range of the linac-based Lattice therapy. HCND_A was a constant, TBRT delivered one high dose core for every 1 cm2 of tumor bed. All dose metrics in both the CTV_5mm and CTV_5mm_Eval were largely consistent across all plans. Conclusions: TBRT produced heterogeneous dose distributions comparable to conventional SFRT. A 60 Gy TBRT nominal prescription dose approximated the SFRT D90, or valley dose of the 5 mm expansion target volume, suggesting TBRT may provide an SFRT platform for tile-accessible cancers.
- 21 February 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (4) , 853
A Personalized Approach to Spinal Cord Ependymoma
- 21 February 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 121 (4) , 853
A Personalized Approach to Spinal Cord Ependymoma
- 28 November 2024
- Published by Springer Nature
- p. 299-324
Skull Base Tumors
- 28 November 2024
- Published by Springer Nature
- p. 429-451
Adult Medulloblastoma
- 28 November 2024
- Published by Springer Nature
- p. 389-404
Germ Cell Tumors
- Open Access
The Role of CT and MR Imaging in Stereotactic Body Radiotherapy of the Spine: From Patient Selection and Treatment Planning to Post-Treatment Monitoring
Spine metastases (SMs) are common, arising in 70% of the cases of the most prevalent malignancies in males (prostate cancer) and females (breast cancer). Stereotactic body radiotherapy, or SBRT, has been incorporated into clinical treatment algorithms over the past decade. SBRT has shown promising rates of local control for oligometastatic spinal lesions with low radiation dose to adjacent critical tissues, particularly the spinal cord. Imaging is critically important in SBRT planning, guidance, and response monitoring. This paper reviews the roles of imaging in spine SBRT, including conventional and advanced imaging approaches for SM detection, treatment planning, and post-SBRT follow-up.
Open AccessThe Role of CT and MR Imaging in Stereotactic Body Radiotherapy of the Spine: From Patient Selection and Treatment Planning to Post-Treatment Monitoring
Spine metastases (SMs) are common, arising in 70% of the cases of the most prevalent malignancies in males (prostate cancer) and females (breast cancer). Stereotactic body radiotherapy, or SBRT, has been incorporated into clinical treatment algorithms over the past decade. SBRT has shown promising rates of local control for oligometastatic spinal lesions with low radiation dose to adjacent critical tissues, particularly the spinal cord. Imaging is critically important in SBRT planning, guidance, and response monitoring. This paper reviews the roles of imaging in spine SBRT, including conventional and advanced imaging approaches for SM detection, treatment planning, and post-SBRT follow-up.
- Open Access
- 9 March 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (7) , 1195-1212
Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
The American Radium Society (ARS) Central Nervous System (CNS) committee reviewed literature on epidermal growth factor receptor mutated (EGFRm) and ALK-fusion (ALK+) tyrosine kinase inhibitors (TKIs) for the treatment of brain metastases (BrMs) from non-small cell lung cancers (NSCLC) to generate appropriate use guidelines addressing use of TKIs in conjunction with or in lieu of radiotherapy (RT). The panel developed three key questions to guide systematic review: can radiotherapy be deferred in patients receiving EGFR or ALK TKIs at (1) diagnosis or (2) recurrence? Should TKI be administered concurrently with RT (3)? Two literature searches were performed (May 2019 and December 2023). The panel developed 8 model cases and voted on treatment options using a 9-point scale, with 1–3, 4–6 and 7–9 corresponding to usually not appropriate, may be appropriate, and usually appropriate (respectively), per the UCLA/RAND Appropriateness Method. Consensus was achieved in only 4 treatment scenarios, all consistent with existing ARS-AUC guidelines for multiple BrM. The panel did not reach consensus that RT can be appropriately deferred in patients with BrM receiving CNS penetrant ALK or EGFR TKIs, though median scores indicated deferral may be appropriate under most circumstances. Whole brain RT with concurrent TKI generated broad disagreement except in cases with 2–4 BrM, where it was considered usually not appropriate. We identified no definitive studies dictating optimal sequencing of TKIs and RT for EGFRm and ALK+ BrM. Until such studies are completed, the committee hopes these cases guide decision- making in this complex clinical space.
- 9 March 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (7) , 1195-1212
Open AccessExecutive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
The American Radium Society (ARS) Central Nervous System (CNS) committee reviewed literature on epidermal growth factor receptor mutated (EGFRm) and ALK-fusion (ALK+) tyrosine kinase inhibitors (TKIs) for the treatment of brain metastases (BrMs) from non-small cell lung cancers (NSCLC) to generate appropriate use guidelines addressing use of TKIs in conjunction with or in lieu of radiotherapy (RT). The panel developed three key questions to guide systematic review: can radiotherapy be deferred in patients receiving EGFR or ALK TKIs at (1) diagnosis or (2) recurrence? Should TKI be administered concurrently with RT (3)? Two literature searches were performed (May 2019 and December 2023). The panel developed 8 model cases and voted on treatment options using a 9-point scale, with 1–3, 4–6 and 7–9 corresponding to usually not appropriate, may be appropriate, and usually appropriate (respectively), per the UCLA/RAND Appropriateness Method. Consensus was achieved in only 4 treatment scenarios, all consistent with existing ARS-AUC guidelines for multiple BrM. The panel did not reach consensus that RT can be appropriately deferred in patients with BrM receiving CNS penetrant ALK or EGFR TKIs, though median scores indicated deferral may be appropriate under most circumstances. Whole brain RT with concurrent TKI generated broad disagreement except in cases with 2–4 BrM, where it was considered usually not appropriate. We identified no definitive studies dictating optimal sequencing of TKIs and RT for EGFRm and ALK+ BrM. Until such studies are completed, the committee hopes these cases guide decision- making in this complex clinical space.
- Open Access
- 19 May 2023
- Published by MDPI AG in Preprints.org
Treating Cylindrically Populated Endometrial Cancers With High Dose Rate Vaginal Cuff Brachytherapy: Should We Use a MulTi-Channel or Single-Channel Cylinder?
Purpose: The purpose of this study was to evaluate the dosimetric impact of multiple channels compared to a single channel in high dose rate (HDR) vaginal cuff brachytherapy (VCBT). Methods and materials: Sample plans of HDR VCBT from both single and multiple channel cylinders at 2.5, 3.0 and 3.5 cm in diameter were created and analyzed. The doses were prescribed either at the 0.5 cm depth with 5.5 Gy for 4 fractions or at the cylinder surface with 8.8 Gy for 4 frac¬tions, in various treatment lengths ranging from 3 to 8 cm. A 0.5 cm ring target volume called PTV_Eval was contoured for each plan and served as the target volume for dosimetric evaluation. Mean doses and the doses covering 90% (D90), 10% (D10), and 5% (D5) of PTV_Eval were calculated and compared. The same treatment lengths, same prescription regimens, same target volume contouring and same plan evaluation methods were repeated for the similar size single channel and multiple channel cylinders. Results: The mean doses of both regimens with the multi-channel cases (6.3 to 7.1 Gy) were comparable to single channel ones (6.4 and 7.5 Gy). The ranges of D90, D10 and D5 were from 3.654 to 5.04 Gy, 8.44 to 10.08 Gy and 8.84 to 10.86 Gy in the multi-channel cases, but from 5.36 to 5.76 Gy, 7.40 to 9.97 Gy and 8.16 to 11.93 Gy in the single channel cases, respectively. Conclusion: The single channel and multiple-channel cylinder deliver a similar mean dose, but with marked heterogeneity in D90, D5 and D10 for the same prescription dose and target volume. Multi-channel cylinders adequately cover the target volume, but given the heterogeneity, increased treatment time and cost are best suited for asymmetric target volumes.
- 19 May 2023
- Published by MDPI AG in Preprints.org
Open AccessTreating Cylindrically Populated Endometrial Cancers With High Dose Rate Vaginal Cuff Brachytherapy: Should We Use a MulTi-Channel or Single-Channel Cylinder?
Purpose: The purpose of this study was to evaluate the dosimetric impact of multiple channels compared to a single channel in high dose rate (HDR) vaginal cuff brachytherapy (VCBT). Methods and materials: Sample plans of HDR VCBT from both single and multiple channel cylinders at 2.5, 3.0 and 3.5 cm in diameter were created and analyzed. The doses were prescribed either at the 0.5 cm depth with 5.5 Gy for 4 fractions or at the cylinder surface with 8.8 Gy for 4 frac¬tions, in various treatment lengths ranging from 3 to 8 cm. A 0.5 cm ring target volume called PTV_Eval was contoured for each plan and served as the target volume for dosimetric evaluation. Mean doses and the doses covering 90% (D90), 10% (D10), and 5% (D5) of PTV_Eval were calculated and compared. The same treatment lengths, same prescription regimens, same target volume contouring and same plan evaluation methods were repeated for the similar size single channel and multiple channel cylinders. Results: The mean doses of both regimens with the multi-channel cases (6.3 to 7.1 Gy) were comparable to single channel ones (6.4 and 7.5 Gy). The ranges of D90, D10 and D5 were from 3.654 to 5.04 Gy, 8.44 to 10.08 Gy and 8.84 to 10.86 Gy in the multi-channel cases, but from 5.36 to 5.76 Gy, 7.40 to 9.97 Gy and 8.16 to 11.93 Gy in the single channel cases, respectively. Conclusion: The single channel and multiple-channel cylinder deliver a similar mean dose, but with marked heterogeneity in D90, D5 and D10 for the same prescription dose and target volume. Multi-channel cylinders adequately cover the target volume, but given the heterogeneity, increased treatment time and cost are best suited for asymmetric target volumes.
- 22 October 2022
- Published by Springer Nature
- p. 345-354
Brain Metastases
- Open Access
- 16 October 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 160 (1) , 241-251
A quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes
Purpose Brain metastases (BM) remain a significant cause of morbidity and mortality in breast cancer (BC) patients. Specific factors promoting the process of BM and predilection for selected neuro-anatomical regions remain unknown, yet may have major implications for prevention or treatment. Anatomical spatial distributions of BM from BC suggest a predominance of metastases in the hindbrain and cerebellum. Systematic approaches to quantifying BM location or location-based analyses based on molecular subtypes, however, remain largely unavailable. Methods We analyzed stereotactic Cartesian coordinates derived from 134 patients undergoing gamma- knife radiosurgery (GKRS) for treatment of 407 breast cancer BMs to quantitatively study BM spatial distribution along principal component axes and by intrinsic molecular subtype (ER, PR, Herceptin). We used kernel density estimators (KDE) to highlight clustering and distribution regions in the brain, and we used the metric of mutual information (MI) to tease out subtle differences in the BM distributions associated with different molecular subtypes of BC. BM location maps according to vascular and anatomical distributions using Cartesian coordinates to aid in systematic classification of tumor locations were additionally developed. Results We corroborated that BC BMs show a consistent propensity to arise posteriorly and caudally, and that Her2+ tumors are relatively more likely to arise medially rather than laterally. To compare the distributions among varying BC molecular subtypes, the mutual information metric reveal that the ER−PR−Her2+ and ER−PR−Her2− subtypes show the smallest amount of mutual information and are most molecularly distinct. The kernel density contour plots show a propensity for triple negative BC to arise in more superiorly or cranially situated BMs. Conclusions We present a novel and shareable workflow for characterizing and comparing spatial distributions of BM which may aid in identifying therapeutic or diagnostic targets and interactions with the tumor microenvironment. Further characterization of these patterns with larger multi-institutional data-sets may have major impacts on treatment or management of cancer patients.
- 16 October 2022
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 160 (1) , 241-251
Open AccessA quantitative characterization of the spatial distribution of brain metastases from breast cancer and respective molecular subtypes
Purpose Brain metastases (BM) remain a significant cause of morbidity and mortality in breast cancer (BC) patients. Specific factors promoting the process of BM and predilection for selected neuro-anatomical regions remain unknown, yet may have major implications for prevention or treatment. Anatomical spatial distributions of BM from BC suggest a predominance of metastases in the hindbrain and cerebellum. Systematic approaches to quantifying BM location or location-based analyses based on molecular subtypes, however, remain largely unavailable. Methods We analyzed stereotactic Cartesian coordinates derived from 134 patients undergoing gamma- knife radiosurgery (GKRS) for treatment of 407 breast cancer BMs to quantitatively study BM spatial distribution along principal component axes and by intrinsic molecular subtype (ER, PR, Herceptin). We used kernel density estimators (KDE) to highlight clustering and distribution regions in the brain, and we used the metric of mutual information (MI) to tease out subtle differences in the BM distributions associated with different molecular subtypes of BC. BM location maps according to vascular and anatomical distributions using Cartesian coordinates to aid in systematic classification of tumor locations were additionally developed. Results We corroborated that BC BMs show a consistent propensity to arise posteriorly and caudally, and that Her2+ tumors are relatively more likely to arise medially rather than laterally. To compare the distributions among varying BC molecular subtypes, the mutual information metric reveal that the ER−PR−Her2+ and ER−PR−Her2− subtypes show the smallest amount of mutual information and are most molecularly distinct. The kernel density contour plots show a propensity for triple negative BC to arise in more superiorly or cranially situated BMs. Conclusions We present a novel and shareable workflow for characterizing and comparing spatial distributions of BM which may aid in identifying therapeutic or diagnostic targets and interactions with the tumor microenvironment. Further characterization of these patterns with larger multi-institutional data-sets may have major impacts on treatment or management of cancer patients.